Clinical Implication of the Effect of the Production of Neutralizing Antibodies Against SARS-Cov-2 for Chronic Immune Thrombocytopenia Flare-Up Associated with COVID-19 Infection: A Case Report and the Review of Literature

References

• Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386–2393. doi:10.1182/blood-2008-07-162503
   PubMed Web of Science ®Google Scholar
• Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med. 2002;346:995–1008. doi:10.1056/NEJMra010501
   PubMed Web of Science ®Google Scholar
• Liebman HA. Viral-associated immune thrombocytopenic purpura. Am Soc Hematol Educ Program Book. 2008;2008:212–218. doi:10.1182/asheducation-2008.1.212
   Google Scholar
• Lee EJ, Liu X, Hou M, Bussel JB. Immune thrombocytopenia during the COVID-19 pandemic. Br J Haematol. 2021;193:1093–1095. doi:10.1111/bjh.17457
   Web of Science ®Google Scholar
• Merli M, Ageno W, Sessa F, et al. Recurrence of immune thrombocytopenia at the time of SARS-CoV-2 infection. Ann Hematol. 2020;99:1951–1952. doi:10.1007/s00277-020-04130-2
   PubMed Web of Science ®Google Scholar
• Hu Z, Chen W, Liang W, Xu C, Sun W, Yi Y. Severe exacerbation of immune thrombocytopenia and COVID-19: the favorable response to corticosteroid-based therapy-A case report. Ann Hematol. 2021;100:2135–2137. doi:10.1007/s00277-020-04070-x
   Web of Science ®Google Scholar
• Pantic N, Suvajdzic-Vukovic N, Virijevic M, et al. Coronavirus disease 2019 in patients with chronic immune thrombocytopenia on thrombopoietin receptor agonists: new perspectives and old challenges. Blood Coagul Fibrinolysis. 2022;33:51–55. doi:10.1097/MBC.0000000000001109
   Web of Science ®Google Scholar
• Dogan M, Kozhaya L, Placek L, et al. SARS-CoV-2 specific antibody and neutralization assays reveal the wide range of the humoral immune response to the virus. Commun Biol. 2021;4:129. doi:10.1038/s42003-021-01649-6
   Web of Science ®Google Scholar
• Pang NY, Pang AS, Chow VT, Wang DY. Understanding neutralizing antibodies against SARS-CoV-2 and their implications in clinical practice. Mil Med Res. 2021;8:47. doi:10.1186/s40779-021-00342-3
   PubMed Web of Science ®Google Scholar
• Dispinseri S, Secchi M, Pirillo MF, et al. Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival. Nat Commun. 2021;12:2670. doi:10.1038/s41467-021-22958-8
   PubMed Web of Science ®Google Scholar
• Yuan M, Yin W, Tao Z, Tan W, Hu Y, Schildgen O. Association of radiologic findings with mortality of patients infected with 2019 novel coronavirus in Wuhan, China. PLoS One. 2020;15(3):e0230548. doi:10.1371/journal.pone.0230548
   PubMed Web of Science ®Google Scholar
• Marshall JC, Murthy S, Diaz J, et al. WHO Working Group on the clinical characterisation and management of COVID-19 infection. Lancet Infect Dis. 2020;20:192–197.
   PubMed Web of Science ®Google Scholar
• Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507–513. doi:10.1016/S0140-6736(20)30211-7
   PubMed Web of Science ®Google Scholar
• Guan WJ, Ni ZY, Hu Y, et al. China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382:1708–1720. doi:10.1056/NEJMoa2002032
   PubMed Web of Science ®Google Scholar
• Bomhof G, Mutsaers PGNJ, Leebeek FWG, et al. COVID-19-associated immune thrombocytopenia. Br J Haematol. 2020;190:61–64. doi:10.1111/bjh.16850
   PubMed Web of Science ®Google Scholar
• Pedroso A, Frade L, Trevas S, Correia MJ, Esteves AL. Immune thrombocytopenic purpura - different presentations in two COVID-19 patients. Cureus. 2020;12:11202.
   PubMed Web of Science ®Google Scholar
• Watts A, Raj K, Gogia P, Toquica Gahona CC, Porcelli M. Secondary Immune thrombocytopenic purpura triggered by COVID-19. Cureus. 2021;13:14505.
   Web of Science ®Google Scholar
• Ali E, Al-Maharmeh Q, Rozi WM, Habib MB, Yassin M. Immune thrombocytopenia purpura flare post COVID-19 vaccine. Ann Med Surg. 2021;6:103164.
   Google Scholar
• Shah SRA, Dolkar S, Mathew J, Vishnu P. COVID-19 vaccination associated severe immune thrombocytopenia. Exp Hematol Oncol. 2021;10:42. doi:10.1186/s40164-021-00235-0
   PubMed Web of Science ®Google Scholar
• Helms JM, Ansteatt KT, Roberts JC, et al. Severe, refractory immune thrombocytopenia occurring after SARS-CoV-2 vaccine. J Blood Med. 2021;12:221–224. doi:10.2147/JBM.S307047
   PubMed Web of Science ®Google Scholar
• Levavi H, Lancman G, Gabrilove J. Impact of rituximab on COVID-19 outcomes. Ann Hematol. 2021;100(11):2805–2812. doi:10.1007/s00277-021-04662-1
   PubMed Web of Science ®Google Scholar
• Yasuda H, Tsukune Y, Watanabe N, et al. Persistent COVID-19 pneumonia and failure to develop anti-SARS-CoV-2 antibodies during rituximab maintenance therapy for follicular lymphoma. Clin Lymphoma Myeloma Leuk. 2020;20:774–776. doi:10.1016/j.clml.2020.08.017
   Web of Science ®Google Scholar
• Cattaneo C, Cancelli V, Imberti L, et al. Production and persistence of specific antibodies in COVID-19 patients with hematologic malignancies: role of rituximab. Blood Cancer J. 2021;11:151. doi:10.1038/s41408-021-00546-9
   Web of Science ®Google Scholar
• Horiuchi H, Sasaki H, Miyazaki K, Miyata N, Yoshimura Y, Tachikawa N. Recovery from severe persistent COVID-19 without evidence of an anti-SARS-CoV-2 antibody response in a man with mantle cell lymphoma treated with rituximab. J Infect Chemother. 2022;28:329–332. doi:10.1016/j.jiac.2021.11.018
   Web of Science ®Google Scholar
• Horiuchi H, Morishita E, Urano T, Yokoyama K. Questionnaire-survey joint team on the COVID-19-related thrombosis. COVID-19-related thrombosis in Japan: final report of a questionnaire-based survey in 2020. J Atheroscler Thromb. 2021;28:406–416. doi:10.5551/jat.RPT001
   Web of Science ®Google Scholar
• Klok FA, Kruip MJHA, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145–147. doi:10.1016/j.thromres.2020.04.013
   PubMed Web of Science ®Google Scholar